Studies combining M2T-CD33 with the AML SOC chemotherapy agent Ara-C/cytarabine and an anti-PD-1 antibody showed promising combination activity, positioning M2T-CD33 for clinical trials as both a single agent and in combination with existing SOC and other immunotherapies. The gene discussed is CD33; the disease is acute myeloid leukemia.